WithdrawnPhase 2/3

Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis

Stopped: Study Period Ended/Not Completed

United States0Started 2019-07-30

Plain-language summary

Allergic rhinitis is defined as the symptoms of sneezing, nasal itching, airflow obstruction, and, mostly, clear nasal discharge caused by IgE-mediated reactions against inhaled allergens and involving mucosal inflammation driven by T cells (Th2) auxiliary type 2. pollens and molds, as well as allergens from perennial interiors, such as dust mites, pets, pests, and some molds. The pattern of dominant allergens depends on the geographic region and degree of urbanization, but the general prevalence of sensitization to allergens does not vary among census districts in the United States. This research proposes to study a separate antihistamine in a nasal spray. It is important to note that this antihistamine is available without prescription (OTC) and has been studied intranasal since the 1950s1

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. No oral steroids
✓. No oral antihistamine
✓. No Nafasoline If the patient needs rescue treatment, he will go to the intervention arm with chlorpheniramine or with the combination of chlorpheniramine and fluticasone. If a participant experienced a severe acute nasal block, the investigator could authorize the use of a short course of oxymetazoline spray for a maximum of 3 days and a maximum total of 1 day during the treatment period. Oxymetazoline should not be used within 24 hours of a scheduled visit during the study.

Exclusion criteria

✕. Large (grade 3) polyps, indicating severe nasal obstruction
✕. Surgical treatment for nasal polyps during the last 3 months
✕. Cystic fibrosis
✕. Purulent nasal infection
✕. Allergic rhinitis
✕. Any disease likely to interfere with the study parameters or which gave evidence of any serious or unstable concurrent disease or psychological disorder

What they're measuring

Daily Symptom Score (DSS)

Timeframe: 30 days

Visual Analogue Scale (VAS)

Timeframe: 30 days

Trial details

NCT IDNCT04790487

SponsorLarkin Community Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-30

View on ClinicalTrials.gov More Allergic Rhinitis trials